Evidence map›Paper›PMID 42273754›Full record

ArticleJournal of intellectual disability research : JIDR2026

Metabolomic Profiles in Down Syndrome: A Scoping Review of Convergent and Context-Dependent Patterns.

Carolina Gastélum Guerrero, Alma M Guadrón Llanos, Loranda Calderón Zamora, Alberto K De la Herrán Arita, Yair Cruz Narváez, Gisela Duarte de la Peña, Javier A Magaña Gómez

Abstract readScoping Review
In one paragraph

Article in Journal of intellectual disability research : JIDR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Carolina Gastélum GuerreroPosgrado en Ciencias en Biomedicina Molecular, Facultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, Mexico.ORCID https://orcid.org/0009-0006-8221-0272
Alma M Guadrón LlanosFacultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, Mexico.ORCID https://orcid.org/0000-0003-4782-6398
Loranda Calderón ZamoraFacultad de Biología, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, Mexico.ORCID https://orcid.org/0000-0001-7423-2283
Alberto K De la Herrán AritaFacultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, Mexico.ORCID https://orcid.org/0000-0002-2307-0648
Yair Cruz NarváezLaboratorio de Posgrado e Investigación de Operaciones Unitarias, Escuela Superior de Ingeniería Química e Industrias Extractivas, Instituto Politécnico Nacional Zacatenco, Ciudad de México, Mexico.ORCID https://orcid.org/0000-0003-0956-645X
Gisela Duarte de la PeñaPrograma Educativo de Nutrición, Universidad Autónoma de Occidente, Culiacán, Sinaloa, Mexico.ORCID https://orcid.org/0000-0001-5643-2353
Javier A Magaña GómezFacultad de Ciencias de la Nutrición y Gastronomía, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, Mexico.ORCID https://orcid.org/0000-0003-1081-6997

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIndividuals with Down syndrome (DS) face a high burden of health complications, yet the molecular underpinnings remain incompletely defined.

objectiveThe objective of this study is to systematically identify metabolomic changes in individuals with DS and how they relate to DS-associated conditions.

methodsA scoping review of the literature was performed across four online databases to identify studies profiling metabolites in people with DS using untargeted or targeted metabolomics procedures. The findings were narratively synthesised to provide a comprehensive overview of patterns of convergence and variability across studies.

resultsThirty-four studies examining metabolites in individuals with DS were identified. The combined findings revealed widespread disruptions in energy (e.g., tricarboxylic acid cycle intermediates and acylcarnitines), one-carbon (e.g., methionine and the SAM/SAH axis), amino acid (e.g., tryptophan-kynurenine and glutamate/GABA) and lipid (e.g., phospholipids and sphingolipids) metabolism, along with changes in immune and neurotransmitter pathways. These metabolic alterations are associated with phenotypic variability and comorbidities in DS. However, the evidence reflects partially convergent and context-dependent patterns, with substantial variability across studies.

conclusionMetabolic disturbances are common in DS, suggesting candidate metabolic signatures that still require independent replication and validation. Current evidence is predominantly cross-sectional and associative, limiting causal inference. Integrating metabolomics with multi-omics approaches may enhance the understanding of DS-related health issues and support future translation into clinical applications.

Indexed as

Down SyndromeMetabolomeMetabolomicsHumansDown syndromemetabolic pathwaysmetabolomicsomics sciences

Identifiers

PMID42273754
PMCPMC13537337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.